The statin wars: Why AstraZeneca mu...( On Thursday 23 October AstraZeneca on...),Health

On Thursday 23 October, AstraZeneca, one of the world's largest pharmaceutical companies, will announce its third-quarter financial results. This coincides with a robust editorial in this week's issue of THE LANCET which calls into question AstraZeneca's high-profile marketing of rosuvastatin, a drug launched into the global statin market last month on the basis of as yet incomplete research findings.

The editorial comments: 'The statin market is vast. Pfizer's atorvastatin-the world's best-selling drug-had sales in 2002 of US$ 8 billion. AstraZeneca predicts that it can take a 20% share of this global market. It needs to. The company reported a 17% drop in pre-tax profits in the second quarter of this year. After a damaging delay over safety concerns, rosuvastatin finally won US FDA approval in August and was launched last month, winning a 2% market share after only three weeks. [Tom] McKillop [AstraZeneca's Chief Executive] has pledged to do whatever it takes to persuade doctors to prescribe rosuvastatin, including launching an estimated $1 billion first-year promotional campaign. "We've got to drive the momentum", he said at a recent investors meeting. "You get one shot at launching a major new product. This is our shot."'

Galaxy-the umbrella consortium of randomised trials that have tested rosuvastatin in different clinical settings-is the marketing tool for the drug; the Lancet editorial points out weaknesses of many of the trials, commenting that 'with no clinical end-point trial yet completed, the company has chosen to market rosuvastatin by applying adventurous statistics to an overinterpreted syllogism.'

The editorial concludes: 'Since there are no reliable data about efficacy and safety-and AstraZeneca is facing unusually acute commercial pressure to force rosuvastatin into the market-doctors should pause before prescribing this drug. Physicians must tell their patients the truth about rosuvastatin-that, compared with its co
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
23-Oct-2003

Page: 1 2
Related medicine news :

1. Hepatotoxicity and statins
2. Jefferson scientists help explain statins effects in Alzheimers disease
3. Reduced progression of atherosclerosis tied to statin drugs lowering fats, protein
4. Risk of muscle-damaging disorder low for most commonly prescribed statin drugs
5. Jefferson scientists uncover new evidence to help explain statins effects in Alzheimers disease
6. CRESTOR leads in 1st international prospective study of statins in the metabolic syndrome
7. OTC statins: A bad decision for public health
8. ESC highlights need for screening and global risk management as statins move over the counter in UK
9. ACP guidelines: Many diabetics should be taking statins
10. Erectile dysfunction has devastating effect on morale
11. New insights into devastating basketball foot injury